These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28189417)

  • 21. Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization.
    Lukaszuk K; Kunicki M; Liss J; Lukaszuk M; Jakiel G
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):173-7. PubMed ID: 23485092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?
    Kara M; Aydin T; Aran T; Turktekin N; Ozdemir B
    Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():63-5. PubMed ID: 24331115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimüllerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization.
    Hamdine O; Eijkemans MJC; Lentjes EGW; Torrance HL; Macklon NS; Fauser BCJM; Broekmans FJ
    Fertil Steril; 2015 Oct; 104(4):891-898.e2. PubMed ID: 26196233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
    Majumder K; Gelbaya TA; Laing I; Nardo LG
    Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Low circulating anti-Müllerian hormone and normal follicle stimulating hormone levels: which prognosis in an IVF program?].
    Grzegorczyk-Martin V; Khrouf M; Bringer-Deutsch S; Mayenga JM; Kulski O; Cohen-Bacrie P; Benaim JL; Belaisch-Allart J
    Gynecol Obstet Fertil; 2012; 40(7-8):411-8. PubMed ID: 22521986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can the fall in serum FSH during coasting in IVF/ICSI predict clinical outcomes?
    Datta AK; Zosmer A; Tozer A; Sabatini L; Davis C; Al-Shawaf T
    Reprod Biomed Online; 2012 May; 24(5):503-10. PubMed ID: 22417663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High live birth rate in the subsequent IVF cycle after first-cycle poor response among women with mean age 35 and normal FSH.
    Moolenaar LM; Mohiuddin S; Munro Davie M; Merrilees MA; Broekmans FJ; Mol BW; Johnson NP
    Reprod Biomed Online; 2013 Oct; 27(4):362-6. PubMed ID: 23953583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do female age and body weight modify the effect of individualized FSH dosing in IVF/ICSI treatment? A secondary analysis of the OPTIMIST trial.
    Leijdekkers JA; van Tilborg TC; Torrance HL; Oudshoorn SC; Brinkhuis EA; Koks CAM; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Broekmans FJM; Eijkemans MJC;
    Acta Obstet Gynecol Scand; 2019 Oct; 98(10):1332-1340. PubMed ID: 31127607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basal follicle stimulating hormone level correlated to age is a good prognostic criterion for the outcome of intracytoplasmic sperm microinjection.
    Kdous M; Merdassi G; Zhioua F; Elloumi H; Kacem K; Zhioua A
    Tunis Med; 2016 Mar; 94(3):181-5. PubMed ID: 27575500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
    Levi-Setti PE; Cavagna M; Bulletti C
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in "standard" patients treated with 150 IU/day during the first cycle.
    Popovic-Todorovic B; Loft A; Ziebe S; Andersen AN
    Acta Obstet Gynecol Scand; 2004 Sep; 83(9):842-9. PubMed ID: 15315596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do ovarian endometriomas affect ovarian response to ovarian stimulation for IVF/ICSI?
    González-Foruria I; Soldevila PB; Rodríguez I; Rodríguez-Purata J; Pardos C; García S; Pascual MÁ; Barri PN; Polyzos NP
    Reprod Biomed Online; 2020 Jul; 41(1):37-43. PubMed ID: 32456967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nomogram to predict FSH starting dose in poor ovarian response women in progestin primed ovarian stimulation protocol.
    Wu S; Li Y; Wu G; Wu H
    BMC Womens Health; 2023 Apr; 23(1):202. PubMed ID: 37118751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.
    Huber M; Hadziosmanovic N; Berglund L; Holte J
    Fertil Steril; 2013 Nov; 100(5):1270-6. PubMed ID: 23931964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association between anti-Müllerian hormone and IVF-ICSI outcome in poor responder patients performing long protocol.
    Aydin T; Kara M; Aran T; Turktekin N; Ozdemir B
    Clin Exp Obstet Gynecol; 2015; 42(5):663-5. PubMed ID: 26524819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.